<Suppliers Price>

SNDX-5613

Names

[ CAS No. ]:
2169919-21-3

[ Name ]:
SNDX-5613

Biological Activity

[Description]:

SNDX-5613 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Epigenetics >> Epigenetic Reader Domain

[Target]

Menin-MLL[1]


[In Vivo]

SNDX-5613 shows in vivo plasma IC50 of 53 nM. SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts[1].

[References]

[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).

Chemical & Physical Properties

[ Molecular Formula ]:
C32H47FN6O4S

[ Molecular Weight ]:
630.82

[ Storage condition ]:
-20°C


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.